Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $19.68 in the last session, up 5.02% from day before closing price of $18.74. In other words, the price has increased by $5.02 from its previous closing price. On the day, 1.09 million shares were traded. ARWR stock price reached its highest trading level at $19.77 during the session, while it also had its lowest trading level at $18.655.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 4.59 whereas as Long-Term Debt/Eq ratio is at 4.56.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 23 ’25 when OLUKOTUN ADEOYE Y sold 959 shares for $21.00 per share. The transaction valued at 20,139 led to the insider holds 35,781 shares of the business.
OLUKOTUN ADEOYE Y bought 959 shares of ARWR for $20,108 on Jan 23 ’25. On Jan 06 ’25, another insider, Hamilton James C, who serves as the Chief Discovery/Trans Medicine of the company, sold 32,729 shares for $19.82 each. As a result, the insider received 648,824 and left with 272,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2461436672 and an Enterprise Value of 2644916480. For the stock, the TTM Price-to-Sale (P/S) ratio is 693.36 while its Price-to-Book (P/B) ratio in mrq is 13.20. Its current Enterprise Value per Revenue stands at 134.615 whereas that against EBITDA is -4.992.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.92, which has changed by -0.4078989 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $36.72, while it has fallen to a 52-week low of $17.05. The 50-Day Moving Average of the stock is -4.83%, while the 200-Day Moving Average is calculated to be -13.10%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 2.03M shares per day over the past 3-months and 3873600 shares per day over the past 10 days. A total of 124.38M shares are outstanding, with a floating share count of 116.44M. Insiders hold about 6.90% of the company’s shares, while institutions hold 75.89% stake in the company. Shares short for ARWR as of 1731628800 were 9445166 with a Short Ratio of 4.76, compared to 1728950400 on 9334910. Therefore, it implies a Short% of Shares Outstanding of 9445166 and a Short% of Float of 8.9099996.
Earnings Estimates
Arrowhead Pharmaceuticals Inc (ARWR) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.7, with high estimates of $2.64 and low estimates of -$1.51.
Analysts are recommending an EPS of between $1.8 and -$5.73 for the fiscal current year, implying an average EPS of -$3.37. EPS for the following year is -$3.98, with 9.0 analysts recommending between -$2.56 and -$5.04.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $191.57M in the next fiscal year. The high estimate is $350.1M and the low estimate is $43.75M.
